Drug Profile

Research programme: sustained-release siRNA and microRNA therapeutics - Imunon

Alternative Names: EGEN-002; GEN 2; Research programme: sustained-release siRNA anticancer therapeutics - Imunon

Latest Information Update: 21 Sep 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EGEN; SurModics
Developer Imunon
Class MicroRNAs; Small interfering RNA
Mechanism of Action MIRN145-microRNA-inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Lung cancer; Pulmonary arterial hypertension

Most Recent Events

19 Sep 2022 Celsion Corporation is now called Imunon
28 Mar 2019 Celsion acquired all the assets of EGEN
28 Nov 2018 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com